Clinical trials: Repository Corticotropin Injection
Keratoconjunctivitis Sicca
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
The purpose of this pilot study is to assess repository corticotropin injection (RCI) in the form of H.P. Acthar Gel in patients with severe keratoconjunctivitis sicca (KCS, or dry eye disease).
- Trial name
- NCT03398018
- Testing
- repository corticotropin injection
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Systemic Lupus Erythematosus (SLE), Repository Corticotropin Injection
Acthar SLE (Systemic Lupus Erythematosus)
This is a randomized study exploring the efficacy, safety and steroid sparing ability of two doses (40 U and 80 U) of Acthar in SLE patients with immune mediated hematologic manifestations requiring steroid use for a minimum of 2…
- Trial name
- Acthar SLE (NCT02779153)
- Testing
- Acthar low dose (40 U), Acthar high dose (80 U)
- Sponsor
- NYU Langone Health
Uveitis, Posterior, Vasculitis Retinal
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.
- Trial name
- NCT03066869
- Testing
- H.P. ACTHAR GEL
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ocular Immunology and Uveitis Foundation
Rheumatoid Arthritis
Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.
It is hypothesized that repository corticotropin injection in combination with other biologic agents will be able to provide relief of both rheumatoid arthritis and acute exacerbations of rheumatoid arthritis for patients with…
- Trial name
- NCT01966718
- Testing
- Repository corticotropin injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Arthritis Treatment Center, Maryland
Psoriatic Arthritis
Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis
Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label trial with H.P.
- Trial name
- NCT01939132
- Testing
- Open label H.P. Acthar Gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fiechtner, Justus J., M.D., P.C.
Lupus Erythematosus Systemic Exacerbation
Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus
Systemic lupus erythematosus is a serious and potentially life-threatening condition with significant unmet medical need. The aim of this Investigator Initiated, single center, open-label study is to evaluate the efficacy and…
- Trial name
- ACTH (NCT01769937)
- Testing
- H.P. Acthar Gel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fiechtner, Justus J., M.D., P.C.